Cargando…

Therapeutic strategies in RET gene rearranged non-small cell lung cancer

The recent approvals by the Food and Drug Administration several tumor-agnostic drugs have resulted in a paradigm shift in cancer treatment from an organ/histology-specific strategy to biomarker-guided approaches. RET gene fusions are oncogenic drivers in multiple tumor types and are known to occur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drusbosky, Leylah M., Rodriguez, Estelamari, Dawar, Richa, Ikpeazu, Chukwuemeka V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995721/ https://www.ncbi.nlm.nih.gov/pubmed/33771190 http://dx.doi.org/10.1186/s13045-021-01063-9

Ejemplares similares

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer
por: Drusbosky, Leylah M., et al.
Publicado: (2021)

Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update
por: Mendoza, Luis
Publicado: (2018)

Current management of RET rearranged non-small cell lung cancer
por: Stinchcombe, Thomas E
Publicado: (2020)

Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review
por: Puri, Megha, et al.
Publicado: (2023)

Targeting RET-rearranged non-small-cell lung cancer: future prospects
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Zhang, Quxia, et al.
Publicado: (2018)

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
por: Jeon, Youngkyung, et al.
Publicado: (2023)

Efficacy and outcomes of ramucirumab and docetaxel in patients with metastatic non-small cell lung cancer after disease progression on immune checkpoint inhibitor therapy: Results of a monocentric, retrospective analysis
por: Kareff, Samuel A., et al.
Publicado: (2023)

RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
por: Tsuta, K, et al.
Publicado: (2014)

Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with RET Rearrangements
por: Digumarthy, Subba R., et al.
Publicado: (2020)

Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)
por: Takeuchi, Shinji, et al.
Publicado: (2021)

RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer
por: Sasaki, Hidefumi, et al.
Publicado: (2012)

Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
por: Drusbosky, Leylah M., et al.
Publicado: (2020)

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement
por: Zhou, Ning, et al.
Publicado: (2022)

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed
por: Takeda, Masayuki, et al.
Publicado: (2019)

Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions
por: Ackermann, Christoph Jakob, et al.
Publicado: (2019)

Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients
por: Feng, Junnan, et al.
Publicado: (2022)

Targeting RET-rearranged lung cancers with multikinase inhibitors
por: Sabari, Joshua K., et al.
Publicado: (2017)

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
por: Offin, Michael, et al.
Publicado: (2019)

1p/19q codeletion and RET rearrangements in small-cell lung cancer
por: Lu, Hongyang, et al.
Publicado: (2016)

Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes
por: Drusbosky, Leylah M., et al.
Publicado: (2017)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

On the RET Rearrangements in Chernobyl-Related Thyroid Cancer
por: Jargin, Sergei V.
Publicado: (2012)

RET rearrangements are actionable alterations in breast cancer
por: Paratala, Bhavna S., et al.
Publicado: (2018)

RET Fusion Genes in Korean Non-Small Cell Lung Cancer
por: Yoo, Seung Soo, et al.
Publicado: (2013)

Decade in review: a new era for RET-rearranged lung cancers
por: Choudhury, Noura J., et al.
Publicado: (2020)

RET Inhibitors in Non-Small-Cell Lung Cancer
por: Cascetta, Priscilla, et al.
Publicado: (2021)

RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature
por: Baglivo, Sara, et al.
Publicado: (2020)

Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China
por: Li, Tao, et al.
Publicado: (2023)

Atypical Lung Carcinoid With EML4/ALK Fusion Detected With Circulating Tumor DNA
por: Gococo-Benore, Denise A, et al.
Publicado: (2022)

Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients
por: Zhang, Kai, et al.
Publicado: (2019)

Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
por: Fukui, Takafumi, et al.
Publicado: (2022)

The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients
por: Fu, Sha, et al.
Publicado: (2015)

Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study
por: Lu, Chang, et al.
Publicado: (2020)

Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer
por: Rogers, Toni-Maree, et al.
Publicado: (2017)

Rapid and Cost-Efficient Detection of RET Rearrangements in a Large Consecutive Series of Lung Carcinomas
por: Tiurin, Vladislav I., et al.
Publicado: (2023)

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
por: Zhao, Lu, et al.
Publicado: (2022)

Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET–rearranged thyroid cancer
por: Raman, Renuka, et al.
Publicado: (2022)

The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
por: Ke, Jun-yi, et al.
Publicado: (2023)

Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers
por: Hirai, Noriko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dgvh53b2rr3q5p8a23545n5vcb